Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
India’s Sun Pharmaceutical Industries (NSE: SUN) has announced a major acquisition, agreeing to purchase U.S.-based Organon & Co (NYSE: OGN) in an all-cash deal valued at approximately $11.75 billion. The move marks a significant step in Sun Pharma’s strategy to expand its global presence and strengthen its position in key pharmaceutical segments, including women’s health, branded generics, innovative medicines, and biosimilars.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash. This acquisition is expected to significantly enhance Sun Pharma’s product portfolio by adding more than 70 established and innovative medicines across women’s health and general therapeutic areas. Organon’s strong footprint in over 140 international markets will also provide Sun Pharma with broader geographic reach and improved market penetration.
Organon, which was spun off from Merck (NYSE: MRK) in 2021, has demonstrated solid financial performance. The company reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for 2025, making it an attractive target for expansion-focused pharmaceutical companies. By integrating Organon’s assets, Sun Pharma aims to accelerate growth and diversify its revenue streams.
Following the completion of the deal, the combined entity is projected to generate pro forma revenue of around $12.4 billion. This would position Sun Pharma among the top 25 global pharmaceutical companies. Additionally, the acquisition is expected to establish Sun Pharma as a top-three player in the global women’s health market and the seventh-largest company in the biosimilars segment.
Sun Pharma plans to finance the transaction through a combination of internal cash reserves and committed bank financing. The deal has already received approval from both companies’ boards and is expected to close in early 2027, pending regulatory clearances and shareholder approvals. This strategic acquisition underscores Sun Pharma’s ambition to become a leading global pharmaceutical powerhouse while expanding its influence in high-growth therapeutic areas.
